PDCD1 and neoplasm: Combining PARP14i with α-PD-1 treatment also did not seem to alter the course of response unless tumour cells had already been driven to a resistant state by chronic exposure to IFNγ pre-implantation or were progressing upon α-PD-1 treatment, a condition associated with high tumour-intrinsic IFNγ signalling.